Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2006-01-03
2008-09-09
Tsang, Cecilia (Department: 4131)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S579000
Reexamination Certificate
active
07423065
ABSTRACT:
Methods of preventing or reducing hearing or balance loss and damage to ear cells in patients who have been exposed to toxic levels of noise are provided. These methods comprise administering an effective amount of a methionine protective agent, such as D-methionine, prior to, simultaneously with, or subsequently to exposure to noise. Combinations of these time periods can also be employed.
REFERENCES:
patent: 2732400 (1956-01-01), Weiss
patent: 3941818 (1976-03-01), Abdel-Monem
patent: 3962429 (1976-06-01), Furuno et al.
patent: 4426372 (1984-01-01), Borch
patent: 4961926 (1990-10-01), Gabrilove
patent: 5002755 (1991-03-01), Mitchell et al.
patent: 5053429 (1991-10-01), Hirsch et al.
patent: 5122369 (1992-06-01), Dye
patent: 5137712 (1992-08-01), Kask et al.
patent: 5292773 (1994-03-01), Hirsch et al.
patent: 5430064 (1995-07-01), Hirsch et al.
patent: 5466678 (1995-11-01), Kawabata et al.
patent: 5667791 (1997-09-01), Hersh et al.
patent: 5952367 (1999-09-01), Pak
patent: 6177434 (2001-01-01), Kopke et al.
patent: 6187817 (2001-02-01), Campbell
patent: 6265386 (2001-07-01), Campbell
patent: 6649621 (2003-11-01), Kopke et al.
patent: 7071230 (2006-07-01), Cambpell
patent: 2004/0110719 (2004-06-01), Campbell
patent: 2004/0127568 (2004-07-01), Campbell
patent: 2005/0090551 (2005-04-01), Campbell
patent: 2007/0105782 (2007-05-01), Campbell
patent: 0 008 171 (1980-02-01), None
patent: 0 387 757 (1990-09-01), None
patent: 0 482 493 (1992-04-01), None
patent: 0 620 004 (1994-10-01), None
patent: WO 98/14182 (1998-04-01), None
patent: WO 03/045334 (2003-06-01), None
Chu et al., Adenosine Triphosphate (ATP) Induces Other Hair Cell Death Abstr. #294, Association for Research in Otolaryngology, Abstracts of the 20th Annual Midwinger Research Meeting, St. Petersburg Beach, Florida, Feb. 2-6, 1997, p. 74.
Whitworth et al., “Alpha-lipoic acid as a protective agent against ototoxicity;” Abstr. No. 532, Abstracts of the 21st Annual Mid-Winter Research Meeting of the Association for Research in Otolaryngology, Feb. 15-19, 1998, p. 134.
Hayes et al., “Amelioration of renal toxicity of high dose cis-platinum diammine dichloride (CPDD) by mannitol induced diuresis,” Abstr. No. 676, Proc. Am. Assoc. Cancer Res., p. 169 (1976).
Merrin, “A New method to prevent toxicity with high doses of cis diammine platinum (Therapeutic Efficacy in previously treated widespread and recurrent testicular tumors),” Abstr. C-26, Proc. Am. Assoc. Cancer Res., p. 243 (1976).
Sha et al., “Antioxidant therapy attenuates gentamicin-induced ototoxicity,” Abstr. No. 535, Abstracts of the 21st Annual Mid-WInter Research Meeting of the Association for Research in Otolaryngology, Feb. 15-19, 1998, p. 134.
Gessler et al., “Antiradiation effect of S-methylmethionine (Vitamin U),” Prikl. Biokhim. Mikrobiol., 32(6):666-668 (1996).
Campbell et al., “A review of cisplatin protective agents emphasizing nephro- and otoprotectants,” Proposed Review Article Not Yet Submitted for Publication, Including Additional Reference Lists.
Dedon et al., “Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles,” Biochemical Pharmacology, 36(12):1955-1964 (1987).
Infante et al., “Chemical radioprotection on biological important compounds,” Radiation Research, 67(3):637 (1976).
Gandara et al., Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity, Seminars in Oncology, 18(1)(suppl.3):49-55 (1991).
Hannermann et al., Cisplatin-induced lipid peroxidation and decrease of gluconeogenesis in rat kidney cortex: different effects of antioxidants and radical scavengers, Toxicology, 51:119-132 (1988).
Schweitzer, “Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents,” Laryngoscope, 103:1-52 (1993).
Glover et al., “Clinical trials of WR-2721 and cis-platinum,” I.J. Radiation Oncology, Biology, Physics, 16(5):1201-1204 (1989).
Kies et al., “Comparative value of L-, DL-, and D-methionine supplementation of an oat-based diet for humans,” J. Nutr., 105:809-814 (1975).
Jones et al., Coadministration of dimethyl sulfoxide reduces cisplatin nephrotoxicity, Anticancer Research, 11:1939-1942 (1991).
Jones et al., Control of nephrotoxicity in the rat during repeated cis-platinum treatments, Journal of Applied Toxicology, 9(4):229-233 (1989).
Jones et al., Control of nephrotoxicity of cisplatin by clinically used sulfur-containing compounds, Fundamental and Applied Toxicology, 18:181-188 (1992).
Speer et al., “Coordination Complexes of Platinum as Antitumor Agents,” Cancer Chemotherapy Reports, 59(3)(Pt. 1):629-641 (1975).
Ravi et al., Diethyldithiocarbamate protects against cisplatin ototoxicity and nephrotoxicity, Otolaryngology Head and Neck Surgery, Poster 5, 107(2):232 (1992).
Basinger et al., Dithiocarbamate-induced biliary platinum excretion and the control of cis-platinum nephrotoxicity, Toxicology and Applied Pharmacology, 97:279-288 (1989).
Campbell et al., “D-methionine provides excellent protection from cisplatin ototoxicity in rat,” Hearing Research, 102:90-98 (1996).
Campbell et al., D-methionine provides protection against cisplatin damage the rat stria vascularis: a semi-quantitive analysis, Abstr. No. 537, Abstracts of the 21st Annual Mid-winter Research Meeting of the Association for Research in Otolaryngology, Feb. 15-19, 1998, p. 135.
Schein, “Ethyol™ (WR-2721): a chemoprotective agent for platinum anti-cancer drugs,” Speaker Abstracts (XP-002053095).
Gandara et al., Evaluation of cisplatin dose intensity: current status and future prospects, Anticancer Research, 9:1121-1128 (1989).
Alden et al., “Exacerbation of cisplatin-induced nephrotoxicity by methionine” Chem.-Biol. Interactions, 48:121-124 (1984).
Ammash et al., “Inactivation of Aminoglycosides AgainstPseudomonas aeruginosaby a Nutrition Supplementation Solution,” Gen. Pharmac., 25(3):461-466 (1994).
Drobnik et al., “Inactivation of bacteriophages with cis-platinum(II) diamminedichloride,” Chem.-Biol. Interactions, 11:365-375 (1975).
Newman et al., “Inhibition of Biological Activity of Cisplatin by Thiourea and L-Methionine,” J. Clinical Hematology and Oncology, 9(2):208-209 (1979).
Jones et al., Inhibition of cis-diamminedichloroplatinum (II)-induced renal toxicity in the rat Cancer Chemotherapy and Pharmacology, 17:38-42 (1986).
Cardini et al., La radioprotezione dei cromosomi delle midollari umane in vitro, Rabiobiologia Radioterapia E Fisica Medica, 22(6):371-375 (1967).
Basinger et al., “L-methionine antagonism of cis-platinum nephrotoxicity,” Toxicology and Applied Pharmacology, 108:1-15 (1990).
Basinger et al., “L-methionine suppresses pathological sequelae of cis-platinum in the rat,” Fundamental and Applied Toxicology, 14:568-577 (1990).
Walker Jr et al., “Methods of reduction of cisplatin nephrotoxicity,” Annuals of Clinical and Laboratory Science, 11(5):397-409 (1981).
Carrithers et al., “Methylation of Radiation Protector Compounds by Thiol Methyltransferase,” FASEB, 5(4):A824 (1991).
Boogaard et al., “4-methylthiobenzoic acid reduces cisplatin nephrotoxicity in rats without compromising anit-tumor activity,” Biochemical Pharmacology, 41(12):1997-2003 (1991).
Ward et al., “Modification of the renal toxicity of cis-dichlorodiammineplatinum(II) with furosemide in male F344 rats,” Cancer Treatment Reports, 61(3):375-379 (1977).
Zezulka et al., “Nitrogen retention in men fed isolated soybean protein supplemented with L-methionine, D-menthionine, N-acetyl-L-methionine, or inorganic sulfate,” J. Nutr., 106:1286-1291 (1976).
Tognella, Pharmacological interventions to reduce platinum-induced toxicity, Cancer Treatment Reviews, 17:139-142 (1990).
Reser et al., “Physiological evidence for protection from cis-platin oto
Board of Trustees of Southern Illinois University
Klinkel Kortney
Senniger Powers LLP
Tsang Cecilia
LandOfFree
Therapeutic use of methionine-derivitives to reduce the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic use of methionine-derivitives to reduce the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic use of methionine-derivitives to reduce the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3973040